Drug discovery

  • Cantol - Development and validation of new molecules allowing to restore the immune response against cancer cells.

    Immunotherapy, based on therapeutic vaccination against antigens expressed by cancer cells, is at the present time a very promising approach for a small number of cancer patients. The application to a broad scale is however limited by mechanisms of immune suppression that are critical to control to have a therapeutic effect for the greatest number of patients. CANTOL is a research project which aims to discover and validate innovating candidate drugs and additives to inhibit the immune suppression due to the expression of indolamine 2,3 dioxygenase (IDO), in the tumors. The project integrates three activities: A program of discovery of inhibitors of IDO by virtual screening based on the crystalline structure of  IDO and by a traditional in vitro screening of a library of small molecules; A study of inhibitors of IDO in various animal models to validate their application to various pathologies; A proof of concept of the therapeutic application of inhibitors of IDO, provided by a clinical trial in phase I and II studies with 1-methyl tryptophan, a  first generation weak potency IDO inhibitor in patients with lung cancer.

  • Hope4PD - Discovery of new targets for treatment of the Parkinson disease.

    The aim of the HOPE 4 PD project is to validate two G protein coupled receptors (GPCRs) the expression of which is modified in striatum of patients with Parkinson's disease, as targets of drugs for the treatment of neuro-degenerative diseases, Parkinson's disease being the first indication; to identify original compounds able to modulate the activity of these receptors and allow the initiation of an innovating program of drug discovery for Parkinson's disease, up to the development of original chemical molecules and the demonstration of efficacy in animal models. Such a project is made possible by setting up a Walloon consortium involving 5 partners, academic and industrial, whose expertise and combined know how will make it possible to cover all the aspects of the Project, from the discovery and the validation of target up to the development of drugs.